Skip to main content

Table 3 Input Data for discretised HAQ score and continuous ACR: Number of patients N; number of HAQ20 and HAQ50 responders; continuous ACR response ACRcont; + indicates additional treatment with MTX

From: The use of continuous data versus binary data in MTC models: A case study in rheumatoid arthritis

Trial

Arm

N

HAQ20

HAQ50

ACRcont (SD)

Weinblatt et al. [31]

P+

62

30

12

0.08 (0.22)

 

Ada+

69

45

24

0.35 (0.20)

 

Ada+

67

47

26

0.46 (0.22)

 

Ada+

73

52

26

0.42 (0.21)

Keystone et al. [32]

P+

200

95

32

0.13 (0.22)

 

Ada+

212

141

81

0.42 (0.21)

 

Ada+

207

154

82

0.41 (0.21)

Van de Putte et al. [33]

P

110

29

4

0.09 (0.20)

 

Ada

112

47

16

0.31 (0.19)

 

Ada

106

60

19

0.30 (0.19)

 

Ada

103

57

20

0.38 (0.22)

 

Ada

113

60

21

0.33 (0.20)

Miyasaka [34]

P

87

23

8

0.07 (0.17)

 

Ada

87

37

10

0.28 (0.19)

 

Ada

91

39

16

0.33 (0.20)

 

Ada

87

48

18

0.37 (0.21)

Kim et al. [35]

P+

63

28

10

0.18 (0.27)

 

Ada+

65

43

24

0.42 (0.22)

Maini et al. [36]

P+

88

40

9

0.09 (0.19)

 

Inf+

86

40

12

0.35 (0.19)

 

Inf+

86

54

19

0.36 (0.20)

 

Inf+

87

52

23

0.38 (0.21)

 

Inf+

81

48

20

0.37 (0.19)

Westhoven et al. [37]

P+

363

-

-

0.12 (0.23)

 

Inf+

360

-

-

0.37 (0.20)

 

Inf+

361

-

-

0.38 (0.21)

Zhang et al. [38]

P+

86

52

28

0.27 (0.31)

 

Inf+

87

61

39

0.46 (0.20)

Schiff et al. [39]

P+

110

-

-

0.22 (0.29)

 

Inf+

165

-

-

0.41 (0.22)

Moreland et al. [40]

P

80

25

8

0.06 (0.16)

 

Eta

76

47

26

0.34 (0.19)

 

Eta

78

53

31

0.40 (0.21)

Weinblatt et al. [41]

P+

30

16

8

0.10 (0.17)

 

Eta+

59

45

29

0.43 (0.19)

Keystone et al. [42]

P+

133

49

13

0.14 (0.25)

 

Gol

133

56

29

0.30 (0.20)

 

Gol+

89

51

24

0.40 (0.22)

 

Gol+

89

60

31

0.39 (0.21)

Kay et al. [43]

P+

35

-

-

0.14 (0.20)

 

Gol+

35

-

-

0.39 (0.20)

 

Gol+

34

-

-

0.38 (0.21)

Keystone et al. [44]

P+

199

83

35

0.07 (0.20)

 

Cert+

393

263

146

0.40 (0.22)

 

Cert+

390

249

137

0.41 (0.22)

Smolen et al. [45]

P+

127

46

10

0.04 (0.14)

 

Cert+

246

163

66

0.38 (0.21)

 

Cert+

246

155

67

0.38 (0.20)

Fleischmann et al. [46]

P

109

19

2

0.04 (0.14)

 

Cert

111

60

34

0.33 (0.19)

  1. Ada=adalimumab; Inf=infliximab; Eta=etanercept; Gol=golimumab, Cert=certolizumab, P=placebo.